OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation
19 Juillet 2023 - 6:00PM
Business Wire
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE) (Paris:OSE) today announced the publication of its latest
peer-reviewed results on pro-resolutive monoclonal antibody
OSE-230, a novel and innovative approach in the management of the
resolution of chronic and severe inflammation, in the leading
journal Frontiers in Immunology*.
The article, entitled: “ChemR23 activation reprograms
macrophages toward a less inflammatory phenotype and dampens
carcinoma progression”, reports on ChemR23 expression by
Tumor-Associated Macrophages (TAM) and the use of tumor models to
explore OSE-230’s pro-resolutive and non-immunosuppressive activity
in a chronic severe inflammatory situation associated with cancer
and metastasis.
OSE-230’s target, ChemR23, also known as chemerin chemokine-like
receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR), is
expressed by human TAM, the most frequent infiltrating immune cells
in tumors known to modulate pro-tumoral chronic inflammation.
The research demonstrated the reprogramming of TAM through the
activation of ChemR23 by OSE-230. ChemR23 receptor strongly
controls macrophage phenotype and its activation by OSE-230 results
in major remodeling of the tumor immune microenvironment by
limiting macrophages’ immunosuppressive functions, activating T
lymphocyte activity as well as modifying the metastatic niche.
Aurore Morello, Head of Research of OSE Immunotherapeutics,
comments: “We are very pleased with this publication on OSE-230 in
the journal ‘Frontiers in Immunology', a leading journal in its
field which shares impactful immunological discoveries. The
research conducted jointly with the CRCI2NA laboratory (Nantes,
Principal investigators: Christophe Blanquart and Sophie Barille)
has demonstrated the long-term efficacy of OSE-230 based on the
strong expression of ChemR23 in a high inflammatory and severe
chronic model. With occurrence of metastases reduced and overall
survival extended, these data support the durability of OSE-230’s
agonist effect on chronic and severe inflammation. This makes
OSE-230 a first-in-class candidate for IND-enabling studies and
opens its development pathway in various chronic inflammatory
diseases with significant advantage over immunosuppressive
therapies”.
* ChemR23 activation reprograms macrophages toward a less
inflammatory phenotype and dampens carcinoma progression, Frontiers
Immunology Frontiers, Front. Immunol., 19 July 2023, Sec. Cancer
Immunity and Immunotherapy, Volume 14 - 2023
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company dedicated to
developing first-in-class assets in immuno-oncology and
immuno-inflammation.
The Company’s current well-balanced first-in-class clinical
pipeline includes:
- Tedopi® (immunotherapy activating tumor specific
T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is
the Company’s most advanced product; positive results from the
Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients
in secondary resistance after checkpoint inhibitor failure. Other
Phase 2 trials, sponsored by clinical oncology groups, of Tedopi®
in combination are ongoing in solid tumors.
- OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or
lymphomas (first patient included). OSE-279 is the backbone therapy
of the BiCKI® platform.
- OSE-127 - lusvertikimab (humanized monoclonal antibody
antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis
(sponsor OSE Immunotherapeutics); ongoing preclinical research in
leukemia (OSE Immunotherapeutics).
- FR-104/VEL-101 (anti-CD28 monoclonal antibody):
developed in partnership with Veloxis Pharmaceuticals, Inc. in
transplantation; ongoing Phase 1/2 in renal transplant (sponsor
Nantes University Hospital); Phase 1 ongoing in the US (sponsor
Veloxis Pharmaceuticals, Inc.).
- OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on
CD47/SIRPα pathway) developed in partnership with Boehringer
Ingelheim in advanced solid tumors; positive Phase 1 dose
escalation results in monotherapy and in combination, in particular
with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing
clinical trial in combination with ezabenlimab alone or with other
drugs in patients with recurrent/metastatic head and neck squamous
cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).
OSE Immunotherapeutics expects to generate further significant
value from its two proprietary drug discovery platforms, which are
central to its ambitious goal to deliver next-generation
first-in-class immunotherapeutics:
- BiCKI® platform focused on immuno-oncology (IO) is a
bispecific fusion protein platform built on the key backbone
component of anti-PD1 combined with a new immunotherapy target to
increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced
BiCKI® candidate targeting anti-PD1xIL-7.
- Myeloid platform focused on optimizing the therapeutic
potential of myeloid cells in IO and immuno-inflammation (I&I).
OSE-230 (ChemR23 agonist mAb) is the most advanced candidate
generated by the platform, with the potential to resolve chronic
inflammation by driving affected tissues to tissue integrity.
Additional information about OSE Immunotherapeutics assets is
available on the Company’s website: www.ose-immuno.com Click and
follow us on Twitter and LinkedIn
Forward-looking statements This press release contains
express or implied information and statements that might be deemed
forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are
based upon certain assumptions and assessments made by OSE
Immunotherapeutics’ management in light of its experience and its
perception of historical trends, current economic and industry
conditions, expected future developments and other factors they
believe to be appropriate. These forward-looking statements include
statements typically using conditional and containing verbs such as
“expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”,
their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the
forward-looking statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on May 2, 2023, including the annual financial report
for the fiscal year 2022, available on the OSE Immunotherapeutics’
website. Other than as required by applicable law, OSE
Immunotherapeutics issues this press release at the date hereof and
does not undertake any obligation to update or revise the
forward-looking information or statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230719970316/en/
OSE Immunotherapeutics Sylvie Détry
sylvie.detry@ose-immuno.com
Nicolas Poirier Chief Executive Officer
nicolas.poirier@ose-immuno.com
French Media: FP2COM Florence Portejoie
fportejoie@fp2com.fr +33 6 07 768 283
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024